

Meningococcal Polysaccharide Vaccine (MPSV4)

MPSV4 (meningococcal polysaccharide; Menomune®)

Indications for Use and Schedule

- Recommended for persons 56 years of age and older at high risk* for meningococcal disease
- Recommended for persons 2-55 years of age at high risk* for meningococcal disease and MCV4 (meningococcal conjugate vaccine) is contraindicated or unavailable

Revaccination


- Revaccinate persons who received MPSV4 and remain at high risk*. Intervals between doses are:
 - 3 years for children ages 2-6 years
 - 5 years for persons ages 7 years and older
- Use MCV4 when revaccinating persons 2-55 years of age

Vaccine Administration

- Subcutaneous (SC) injection in the upper lateral arm
- 5/8 inch needle; 23-25 gauge
- Professional judgment is appropriate when selecting needle length and site
- Can be administered simultaneously with other vaccines

Storage and Handling

- Store in the refrigerator between 35°-46° F (2°-8°C)
- Do NOT freeze
- Keep in the original box
- Shake well before using
- Requires reconstitution (mixing) prior to administration
- Use only the diluent packaged with this vaccine
- The single dose vial must be used within 30 minutes of Reconstitution
- Multidose vials must be discarded 10 days after reconstitution.



*HIGH RISK CONDITIONS/GROUPS

- College freshmen, living in dormitories
- Persons with functional or anatomic asplenia, or persistent complement component deficiency
- Travelers or residents of countries where meningococcal disease is common, such as parts of Africa
- Persons who may have been exposed to meningitis during an outbreak (except serogroup B outbreaks--not in the vaccine)
- Military recruits
- Lab personnel working with these organisms

CONTRAINDICATIONS

- An anaphylactic reaction to a prior dose of MPSV4 vaccine
- An anaphylactic reaction to a component of MPSV4 vaccine

PRECAUTIONS

- Moderate to severe acute illness

FURTHER POINTS

- Adverse reactions are generally mild- most frequently reported are pain and redness at the injection site
- MPSV4 may be given to persons at high risk for meningococcal disease with a history of Guillain-Barré Syndrome
- MPSV4 contains serotypes A, C, Y, and W-135. Serotype B is not in this vaccine
- Meningococcal Vaccine Information Statement (VIS), can be found at <http://www.immunize.org/vis/>

For additional information, refer to ACIP Recommendations on Vaccines to Prevent Meningococcal Disease, VFC program resolutions located at www.cdc.gov/vaccines.